These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23295934)

  • 1. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model.
    Corvec S; Furustrand Tafin U; Betrisey B; Borens O; Trampuz A
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1421-7. PubMed ID: 23295934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.
    Michail G; Labrou M; Pitiriga V; Manousaka S; Sakellaridis N; Tsakris A; Pournaras S
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6028-33. PubMed ID: 24060874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.
    Oliva A; Furustrand Tafin U; Maiolo EM; Jeddari S; Bétrisey B; Trampuz A
    Antimicrob Agents Chemother; 2014; 58(3):1284-93. PubMed ID: 24145537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae.
    Berçot B; Poirel L; Dortet L; Nordmann P
    J Antimicrob Chemother; 2011 Oct; 66(10):2295-7. PubMed ID: 21807739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae.
    Crémieux AC; Dinh A; Nordmann P; Mouton W; Tattevin P; Ghout I; Jayol A; Aimer O; Gatin L; Verdier MC; Saleh-Mghir A; Laurent F
    J Antimicrob Chemother; 2019 Sep; 74(9):2666-2675. PubMed ID: 31263884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
    Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
    Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia.
    Ku NS; Lee SH; Lim YS; Choi H; Ahn JY; Jeong SJ; Shin SJ; Choi JY; Choi YH; Yeom JS; Yong D; Song YG; Kim JM
    Sci Rep; 2019 Nov; 9(1):17127. PubMed ID: 31748527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
    Endimiani A; Patel G; Hujer KM; Swaminathan M; Perez F; Rice LB; Jacobs MR; Bonomo RA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):526-9. PubMed ID: 19901089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of co-resistance in CTX-M-producing Escherichia coli to non-beta-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden.
    Östholm Balkhed Å; Tärnberg M; Monstein HJ; Hällgren A; Hanberger H; Nilsson LE
    Scand J Infect Dis; 2013 Apr; 45(4):271-8. PubMed ID: 23113731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
    Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
    Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
    Evren E; Azap OK; Çolakoğlu Ş; Arslan H
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Cebrero-Cangueiro T; Álvarez-Marín R; Labrador-Herrera G; Smani Y; Cordero-Matía E; Pachón J; Pachón-Ibáñez ME
    Front Cell Infect Microbiol; 2018; 8():363. PubMed ID: 30406040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
    Fan B; Guan J; Wang X; Cong Y
    PLoS One; 2016; 11(6):e0157757. PubMed ID: 27315107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA).
    Tang HJ; Chen CC; Ko WC; Yu WL; Chiang SR; Chuang YC
    Int J Antimicrob Agents; 2011 Jul; 38(1):46-51. PubMed ID: 21549575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ceftazidime/avibactam in various combinations for the treatment of experimental osteomyelitis in rabbits caused by OXA-48-/ESBL-producing Escherichia coli.
    Davido B; Crémieux AC; Vaugier I; De Truchis P; Hamami K; Laurent F; Saleh-Mghir A
    J Antimicrob Chemother; 2023 May; 78(5):1211-1218. PubMed ID: 36897329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.